Market Overview

UPDATE: Stifel Nicolaus Cuts PT to $26.50 on Endo Health Solutions on Lower Guidance

Related ENDP
Mylan to Settle with Endo on Frova - Analyst Blog
Mylan Says Judge Has Enforced Settlement Deal Between Mylan, Endo Related to Generic FROVA

Stifel Nicolaus reiterated its Buy rating on Endo Health Solutions (NASDAQ: ENDP) but reduced its price target from $40 to $38.

Stifel Nicolaus commented, "As hoped for, Endo finally put forth what we consider realistic guidance following several over-promises in 2012 that culminated in December's guidance pull and a CEO change by May 2013. … Though guidance is lower than our already modest expectations, we favor this conservative outlook on the year, and look for potential strategic shift with the upcoming CEO change. We are reducing our estimates (2013 $4.50, 2014 trough $4.00) and lowering our target price from $40 to $38 to reflect new guidance."

Endo Health Solutions closed at $26.25 on Thursday.

Posted-In: Stifel NicolausAnalyst Color Price Target Intraday Update Analyst Ratings

 

Most Popular

Related Articles (ENDP)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free